Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells

Yasuda, Hiroyasu; Yamaya, Mutsuo; Sasaki, Takuma; Inoue, Daisuke; Nakayama, Katsutoshi; Yamada, Mitsuhiro; Asada, Masanori; Yoshida, Midori; Suzuki, Tomoko; Nishimura, Hideo; Sasaki, Hidetada

doi:10.1183/09031936.06.00058505

Cited by 44 publications

(54 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COPD patients treated with carbocysteine experienced fewer numbers of exacerbations per year (Zheng et al 2008). This effect may be linked to the reduced adherence of bacterial pathogens to airway epithelial cells (Rahman and Macnee 2012) and to the downregulation of ICAM-1, a receptor for the major group of rhinovirus (Yasuda et al 2006). Moreover, carbocysteine inhibiting cell apoptosis and promoting the reversal of the imbalance of proteolytic and anti-proteolytic enzyme activities protects against the development of CSEinduced emphysema in rats (Hanaoka et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells

Pace

Ferraro

Vincenzo

et al. 2013

Cell Stress and Chaperones

View full text Add to dashboard Cite

Cigarette smoke extracts (CSE) induce oxidative stress, an important feature in chronic obstructive pulmonary disease (COPD), and oxidative stress contributes to the poor clinical efficacy of corticosteroids in COPD patients. Carbocysteine, an antioxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on CSE-induced oxidative stress in bronchial epithelial cells as well as the comparison of these antioxidant effects of carbocysteine with those of fluticasone propionate are unknown. The present study was aimed to assess the effects of carbocysteine (10 −4 M) in cell survival and intracellular reactive oxygen species (ROS) production (by flow cytometry) as well as total glutathione (GSH), heme oxygenase-1 (HO-1), nuclearrelated factor 2 (Nrf2) expression and histone deacetylase 2 (HDAC-2) expression/activation in CSE-stimulated bronchial epithelial cells (16-HBE) and to compare these effects with those of fluticasone propionate (10 −8 M). CSE, carbocysteine or fluticasone propionate did not induce cell necrosis (propidium positive cells) or cell apoptosis (annexin Vpositive/propidium-negative cells) in 16-HBE. CSE increased ROS production, nuclear Nrf2 and HO-1 in 16-HBE. Fluticasone propionate did not modify intracellular ROS production, GSH and HDCA-2 but reduced Nrf2 and HO-1 in CSE-stimulated 16-HBE. Carbocysteine reduced ROS production and increased GSH, HO-1, Nrf2 and HDAC-2 nuclear expression/activity in CSE-stimulated cells and was more effective than fluticasone propionate in modulating the CSEmediated effects. In conclusion, the present study provides compelling evidences that the use of carbocysteine may be considered a promising strategy in diseases associated with corticosteroid resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells

Pace

Ferraro

Vincenzo

et al. 2013

Cell Stress and Chaperones

View full text Add to dashboard Cite

show abstract

“…In rhinovirus infections, S-CMC reduces expression of the receptor intercellular adhesion molecule-1 (ICAM-1) and production of cytokines in human tracheal epithelial cells (Yasuda et al, 2006). Additionally, S-CMC reduces the concentration of IL-6 in the breath condensate of acute COPD patients (Carpagnano et al, 2004).…”

Section: Resultsmentioning

confidence: 99%

“…Despite the increase in bacterial adherence to the cells, S-CMC efficiently reduced the enhanced adherence of both strains to the epithelial cells in a dose-dependent manner. These results suggest that the potency of S-CMC against S. pneumoniae adherence contributes to a reduction in COPD symptom exacerbation.In rhinovirus infections, S-CMC reduces expression of the receptor intercellular adhesion molecule-1 (ICAM-1) and production of cytokines in human tracheal epithelial cells (Yasuda et al, 2006). Additionally, S-CMC reduces the concentration of IL-6 in the breath condensate of acute COPD patients (Carpagnano et al, 2004).…”

mentioning

confidence: 99%

S-Carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells

Sumitomo

Nakata

Yamaguchi

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major pathogen of respiratory infections that utilizes platelet-activating factor receptor (PAFR) for firm adherence to host cells. The mucolytic agent S-carboxymethylcysteine (S-CMC) has been shown to exert inhibitory effects against infection by several respiratory pathogens including S. pneumoniae in vitro and in vivo. Moreover, clinical studies have implicated the benefits of S-CMC in preventing exacerbation of chronic obstructive pulmonary disease, which is considered to be related to respiratory infections. In this study, to assess whether the potency of S-CMC is attributable to inhibition of pneumococcal adherence to host cells, an alveolar epithelial cell line stimulated with interleukin-1a was used as a model of inflamed epithelial cells. Despite upregulation of PAFR by inflammatory activation, treatment with S-CMC efficiently inhibited pneumococcal adherence to host epithelial cells. In order to gain insight into the inhibitory mechanism, the effects of S-CMC on PAFR expression were also investigated. Following treatment with S-CMC, PAFR expression was reduced at both mRNA and post-transcriptional levels. Interestingly, S-CMC was also effective in inhibiting pneumococcal adherence to cells transfected with PAFR small interfering RNAs. These results indicate S-CMC as a probable inhibitor targeting numerous epithelial receptors that interact with S. pneumoniae. INTRODUCTIONStreptococcus pneumoniae is a major cause of communityacquired pneumonia, sinusitis and otitis media, and is also associated with acute exacerbations of chronic obstructive pulmonary disease (COPD) (Miravitlles et al., 1999). Among the numerous pneumococcal adherence mechanisms responsible for causing diseases, phosphorylcholine binds specifically to platelet-activating factor receptor (PAFR) expressed on the surface of airway epithelial cells (Cundell et al., 1995(Cundell et al., , 1996Fischer, 2000). Previous in vivo experiments demonstrated that PAFR-deficient mice were less likely to develop invasive disease or had improved host defence during pneumococcal infection (Rijneveld et al., 2004). Therefore, the interaction between PAFR and phosphorylcholine plays a crucial role in the pathogenesis of pneumococcal disease.The mucolytic agent S-carboxymethylcysteine (S-CMC) is widely used as an expectorant in Europe and Asia for the treatment of respiratory diseases with phlegm production. Administration of S-CMC is also effective for COPD patients in terms of reductions in symptom exacerbation and improvements in quality of life (Zheng et al., 2008). It is generally accepted that bacterial colonization is a determinant for COPD exacerbation. Hence, it has been speculated that the potency of S-CMC against respiratory pathogens, including S. pneumoniae (Cakan et al., 2003;Suer et al., 2008), Moraxella catarrhalis (Zheng et al., 1999) and non-typable Haemophilus influenzae (Ndour et al., 2001), contributes to a reduction in episodes of respiratory infection in COPD patients. However, the mechanism by which S-C...

show abstract

“…Carbocysteine may also modulate airway inflammation by reducing the production of cytokines in rhinovirus infections [31]. It has also been shown that carbocysteine inhibits the adherence of bacteria and viruses to ciliated epithelial cells in vitro [31,32].…”

Section: Mucoregulatorsmentioning

confidence: 99%

Mucoactive drugs

Balsamo¹,

Lanata²,

Egan³

2010

Eur Respir Rev

125

102

View full text Add to dashboard Cite

Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Airway mucosal infection and/ or inflammation associated with these diseases often gives rise to inflammatory products, including neutrophil-derived DNA and filamentous actin, in addition to bacteria, apoptotic cells and cellular debris, that may collectively increase mucus production and viscosity. Mucoactive agents have been the medication of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Many mucoactive drugs are currently available and can be classified according to their putative mechanism of action. Mucoactive medications include expectorants, mucoregulators, mucolytics and mucokinetics. By developing our understanding of the specific effects of mucoactive agents, we may result in improved therapeutic use of these drugs. The present review provides a summary of the most clinically relevant mucoactive drugs in addition to their potential mechanism of action.

show abstract

Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells

Cited by 44 publications

References 29 publications

Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells

Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells

S-Carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells

Mucoactive drugs

Contact Info

Product

Resources

About